Peptides for Hair Loss — Evidence Review
Androgenetic alopecia (male and female pattern hair loss) has well-validated first-line therapy: minoxidil, finasteride, dutasteride. None are peptides. The peptide angle for hair loss centers on…
Androgenetic alopecia (male and female pattern hair loss) has well-validated first-line therapy: minoxidil, finasteride, dutasteride. None are peptides. The peptide angle for hair loss centers on copper peptides applied topically — primarily GHK-Cu — and on a small set of peptides with hair-follicle activity in preclinical research.
The honest review: GHK-Cu has real cosmetic and modest hair data; most other peptide hair-loss claims are not supported.
Peptides with the strongest evidence
GHK-Cu (Copper Tripeptide-1)
GHK-Cu has the deepest cosmetic-application literature in the peptide space. Topical application has documented effects on hair follicle activity in preclinical models — increased follicle size, prolonged anagen phase, and growth-factor signaling consistent with hair retention and modest regrowth. Several small human studies show benefit in androgenetic alopecia when combined with minoxidil.
Mechanism: copper peptide complex modulates wound-healing and growth-factor signaling in skin and follicles. Topical formulations are the studied route; injectable use for hair has weaker evidence.
GHK-Cu is broadly available in cosmetic and "research-use" formulations. Quality and concentration vary substantially across products.
Thymosin Beta-4
Animal-model data on hair-follicle stem-cell activation and wound-related regrowth. Some early dermatologic research interest in alopecia areata and androgenetic alopecia. Human trial data is preliminary.
Full thymosin beta-4 profile →
What the evidence does not support
- BPC-157 for hair loss — there is no published evidence of hair-specific effects
- PT-141 or melanocortin agonists for hair — these affect pigmentation but not hair growth
- "Peptide stack" protocols for hair loss combining 3+ injectable peptides without controlled-trial evidence
- Use as a substitute for finasteride/minoxidil in androgenetic alopecia — the evidence for the conventional first-line therapy is much stronger
Practical considerations
If a clinician approves GHK-Cu for adjunctive use:
- Topical application has the strongest evidence base
- Combination with minoxidil has the most studied case
- Compounded topical preparations vary in concentration; pharmacy compounding produces more consistent results than cosmetic-grade products
Finasteride and dutasteride remain first-line for androgenetic alopecia — peptides do not replace them.
Where to source
- GHK-Cu vendor rankings — 14 ranked vendors
For topical use, evaluate concentration and formulation, not just vendor purity.
What we don't know
- Whether GHK-Cu produces clinically meaningful hair regrowth as monotherapy
- Optimal topical concentration and dosing schedule
- Long-term comparative outcomes vs minoxidil + finasteride
- Whether thymosin beta-4 will mature into a clinically useful hair-loss therapy
Methodology
Read the full methodology.
This page is educational. Hair loss is best evaluated by a dermatologist who can distinguish among androgenetic alopecia, alopecia areata, telogen effluvium, scarring alopecias, and nutritional/metabolic causes — each with different treatment.